The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2020 | CITYSCAPE: tiragolumab in NSCLC

Name: CITYSCAPE: tiragolumab in NSCLC
Uploaded: 2020-05-27T00:00:00Z
Duration: 3 min 59 s
Description: Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase II CITYSCAPE study (NCT03563716) of the anti-TIGIT antibody tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Melissa Johnson • 27 May 2020

ASCO 2020

Lung Cancer Non-Small Cell Lung Cancer Tiragolumab

CITYSCAPE

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the phase II CITYSCAPE study (NCT03563716) of the anti-TIGIT antibody tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).